TP53 and B-cell chronic lymphocytic leukemia: However, the efficacy of ibrutinib in previously untreated high-risk CLL carrying 17p- and/or TP53 mutations, here referred to as TP53 aberrations, has been assessed in a limited number of patients enrolled in clinical trials [8, 9].